Biotech Values

[exwannabe]

SPPI presumably tried the old trick of claiming that retaining 50% of the comparator drug’s treatment effect is all one needs to demonstrate non-inferiority, ...

I agree that this is about where it is. I suspect SPPI has now performed some retrospective meta study to try and justify the NI margin used. Odds on this working would not be good,

BTW: This is just an additional indication for Fusilev.